Im Focus Onkologie

, Volume 17, Issue 5, pp 48–54

Im Fokus: die Blockade mit Kinaseinhibitoren

Unerwünschte Ereignisse unter onkologischer Therapie
Fortbildung
  • 11 Downloads

Dank der zielgerichteten Substanzen kann die Behandlung einer Krebserkrankung immer spezifischer und individueller auf den Patienten zugeschnitten werden. Es gilt, diverse Nebenwirkungen im Auge zu haben, die für die Patienten sehr belastend und in seltenen Fällen tödlich sind.

Literatur

  1. 1.
    Yeh TC et al. Biological characterization of ARRY-142886 (AZD6244), a potent, highly selective mitogen-activated protein kinase kinase 1/2 inhibitor. Clin Cancer Res. 2007; 13(5):1576–83.PubMedCrossRefGoogle Scholar
  2. 2.
    Thumar J et al. MEK targeting in N-RAS mutated metastatic melanoma. Mol Cancer. 2014;13:45.PubMedCentralPubMedCrossRefGoogle Scholar
  3. 3.
    Infante JR et al. Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial. Lancet Oncol. 2012;13(8):773–81.PubMedCrossRefGoogle Scholar
  4. 4.
    Leijen S et al. Phase I dose-escalation study of the safety, pharmacokinetics, and pharmacodynamics of the MEK inhibitor RO4987655 (CH4987655) in patients with advanced solid tumors. Clin Cancer Res. 2012;18(17):4794–805.PubMedCrossRefGoogle Scholar
  5. 5.
    Wang D et al. Clinical experience of MEK inhibitors in cancer therapy. Biochim Biophys Acta. 2007;1773(8):1248–55.PubMedCrossRefGoogle Scholar
  6. 6.
    Boasberg PD et al. Pilot study of PD-0325901 in previously treated patients with advanced melanoma, breast cancer, and colon cancer. Cancer Chemother Pharmacol. 2011;68(2):547–52.PubMedCrossRefGoogle Scholar
  7. 7.
    Kramer HF, Goodyear LJ. Exercise, MAPK, and NF-kappaB signaling in skeletal muscle. J Appl Physiol (1985). 2007;103(1):388–95.PubMedCrossRefGoogle Scholar
  8. 8.
    Kirkwood JM et al. Phase II, open-label, randomized trial of the MEK1/2 inhibitor selumetinib as monotherapy versus temozolomide in patients with advanced melanoma. Clin Cancer Res. 2012;18(2):555–67.PubMedCentralPubMedCrossRefGoogle Scholar
  9. 9.
    Balagula Y et al. Dermatologic side effects associated with the MEK 1/2 inhibitor selumetinib (AZD6244, ARRY-142886). Invest New Drugs. 2011;29(5):1114–21.PubMedCrossRefGoogle Scholar
  10. 10.
    Chen X et al. Dropped head syndrome: report of three cases during treatment with a MEK inhibitor. Neurology. 2012;79(18):1929–31.PubMedCentralPubMedCrossRefGoogle Scholar
  11. 11.
    Ascierto PA et al. MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study. Lancet Oncol. 2013;14(3):249–56PubMedCrossRefGoogle Scholar
  12. 12.
    Martinez-Garcia M et al. First-in-human, phase I dose-escalation study of the safety, pharmacokinetics, and pharmacodynamics of RO5126766, a first-in-class dual MEK/RAF inhibitor in patients with solid tumors. Clin Cancer Res. 2012;18(17):4806–19.PubMedCrossRefGoogle Scholar
  13. 13.
    Honda K et al. Phase I and pharmacokinetic/pharmacodynamic study of RO5126766, a first-in-class dual Raf/MEK inhibitor, in Japanese patients with advanced solid tumors. Cancer Chemother Pharmacol. 2013;72(3): 577–84.PubMedCrossRefGoogle Scholar
  14. 14.
    Azad NS et al. Hand-foot skin reaction increases with cumulative sorafenib dose and with combination anti-vascular endothelial growth factor therapy. Clin Cancer Res. 2009;15(4):1411–6PubMedCentralPubMedCrossRefGoogle Scholar
  15. 15.
    Anforth R et al. Cutaneous toxicities of RAF inhibitors. Lancet Oncol. 2013;14(1):e11–8.PubMedCrossRefGoogle Scholar
  16. 16.
    Ascierto PA et al. The role of BRAF V600 mutation in melanoma. J Transl Med. 2012;10:85.PubMedCentralPubMedCrossRefGoogle Scholar
  17. 17.
    Long GV et al. Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial. Lancet Oncol. 2012;13(11):1087–95.PubMedCrossRefGoogle Scholar
  18. 18.
    Goldinger SM et al. Upstream mitogen-activated protein kinase (MAPK) pathway inhibition: MEK inhibitor followed by a BRAF inhibitor in advanced melanoma patients. Eur J Cancer. 2014;50(2):406–10.PubMedCrossRefGoogle Scholar
  19. 19.
    Flaherty KT et al. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N Engl J Med. 2012;367(18):1694–703.PubMedCentralPubMedCrossRefGoogle Scholar
  20. 20.
    Johnson DB et al. Severe cutaneous and neurologic toxicity in melanoma patients during vemurafenib administration following anti-PD-1 therapy. Cancer Immunol Res. 2013;1:373.PubMedCrossRefGoogle Scholar
  21. 21.
    Chappell WH et al. Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR inhibitors: rationale and importance to inhibiting these pathways in human health. Oncotarget. 2011; 2(3):135–64.PubMedCentralPubMedGoogle Scholar
  22. 22.
    Cho DC et al. Two phase 2 trials of the novel Akt inhibitor perifosine in patients with advanced renal cell carcinoma after progression on vascular endothelial growth factor-targeted therapy. Cancer. 2012;118(24):6055–62.PubMedCentralPubMedCrossRefGoogle Scholar
  23. 23.
    Moreno Garcia V et al. Association of creatine kinase and skin toxicity in phase I trials of anticancer agents. Br J Cancer. 2012;107(11):1797–800.PubMedCentralPubMedCrossRefGoogle Scholar
  24. 24.
    Cortes JE et al. Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: results from the BELA trial. J Clin Oncol. 2012;30(28):3486–92.PubMedCrossRefGoogle Scholar
  25. 25.
    Wei G et al. First-line treatment for chronic myeloid leukemia: dasatinib, nilotinib, or imatinib. J Hematol Oncol. 2010;3:47.PubMedCentralPubMedCrossRefGoogle Scholar
  26. 26.
    Petzer AL et al. High-dose imatinib induction followed by standard-dose maintenance in pre-treated chronic phase chronic myeloid leukemia patients—final analysis of a randomized, multicenter, phase III trial. Haematologica. 2012;97(10):1562–9.PubMedCentralPubMedCrossRefGoogle Scholar
  27. 27.
    Joensuu H et al. Practical management of tyrosine kinase inhibitor-associated side effects in GIST. Cancer Treat Rev. 2011;37(1):75–88.PubMedCrossRefGoogle Scholar

Copyright information

© Urban & Vogel 2014

Authors and Affiliations

  1. 1.Klinik für NeurologieEssenDeutschland

Personalised recommendations